Cholangiocarcinoma News

Hot Topics at ASCO-GI 2022

Videos — January 28, 2022


Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
NCI Task Force: Hepatobiliary Cancers
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.

Related Items

CCA Summit Live from ASCO GI 2023
By Stacey Stein, MD
On January 20, 2023, I presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2023). In addition, I provided my perspective on the impact of the data on the management of patients with CCA.
Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Erdafitinib in Asian Patients with Advanced CCA and FGFR Alterations: Updated Analysis
March 2022, Vol 3, No 1
The ongoing open-label, multicenter, phase 2a LUC2001 study is investigating the efficacy and safety of the FGFR inhibitor erdafitinib in a molecularly defined subset of Asian patients with advanced cholangiocarcinoma (CCA) harboring FGFR alterations whose disease progressed after ≥1 previous systemic therapies.
Sitravatinib plus Tislelizumab for Advanced Biliary Tract Cancer in Patients Whose Disease Did Not Respond to at Least 1 Systemic Therapy
March 2022, Vol 3, No 1
Given that monotherapy with immune checkpoint inhibitors, including the PD-1 inhibitor tislelizumab, has a modest effect in advanced biliary tract cancers, several combination strategies to improve the antitumor activity of immune checkpoint inhibitors are being explored.
Systemic Modified FOLFIRINOX Followed by Concurrent Floxuridine and Systemic Modified FOLFIRI in Patients with Unresectable CCA: The HELIX-ICC Study
March 2022, Vol 3, No 1
The majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced liver disease and are not candidates for curative resection. The current standard of care for patients with unresectable intrahepatic CCA is palliative chemotherapy with gemcitabine plus cisplatin.
Tucatinib plus Trastuzumab in Patients with Biliary Tract Cancer and HER2 Expression: Phase 2 Basket Study
March 2022, Vol 3, No 1
Biliary tract cancers have dismal prognosis, and the treatment options are limited. Up to 15% of patients with biliary tract cancer have HER2-positive disease. Tucatinib is a highly selective HER2-­directed tyrosine kinase inhibitor.
Quality-of-Life Trends Associated with Ivosidenib in Patients with CCA and IDH1 Mutation in the ClarIDHy Study
March 2022, Vol 3, No 1
Ivosidenib is a first-in-class inhibitor of IDH1 mutation that is indicated for the treatment of previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and IDH1 mutation. This indication was approved based on the results of the phase 3 ClarIDHy clinical trial, which demonstrated significant improvement in progression-free survival with ivosidenib compared with placebo in patients with previously treated, unresectable or metastatic CCA harboring IDH1 mutations.
Pembrolizumab plus Granulocyte Macrophage Colony-Stimulating Factor in Patients with Advanced Biliary Tract Cancer
March 2022, Vol 3, No 1
Immune checkpoint inhibitors used as monotherapy have dem­onstrated only modest activity in unselected patients with advanced biliary tract cancers, highlighting the need for novel strategies to improve patient outcomes. Granulocyte macrophage colony-stimulating factors (GM-CSF) show immunomodulatory effects and may therefore potentiate the activity of immune checkpoint inhibitors.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: